U.S. License Holder:
Tanvex BioPharma, Inc.
Date of License:
aBLA accepted by FDA October-2021
TX-05 (trastuzumab) is not FDA-approved. An aBLA has been submitted to the FDA.
U.S. Patent LitigationsPACER
U.S. Patent Nos.
8,574,869 (Prevention of Disulfide Bond Reduction During Recombinant Production of Polypeptides) 10,662,237 (Method to Improve Virus Filtration Capacity) 10,808,037 (Prevention of Disulfide Bond Reduction During Recombinant Production of Polypeptides)
Tanvex BioPharma USA, Inc.; Tanvex Biologics Corp.; Tanvex Biologics, Inc.; Tanvex Biopharma, Inc.